Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours |
| |
| Authors: | Lisa Bodei Marta Cremonesi Chiara Grana Paola Rocca Mirco Bartolomei Marco Chinol Giovanni Paganelli |
| |
| Affiliation: | (1) Nuclear Medicine Division, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy;(2) Medical Physics Division, European Institute of Oncology, Milan, Italy |
| |
| Abstract: | Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives. |
| |
| Keywords: | 90Y-DOTATOC Neuroendocrine tumours Receptor radionuclide therapy Somatostatin receptors |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
